"Dendritic Cell-Based Cancer Vaccines In A Chimpanzee Model."

According to an abstract submitted by the authors to the 25th Jubilee Conference of the New Zealand Society for Oncology entitled From Genes to Clinical Trials, held February 13-16, 1996, in Auckland, New Zealand, "MUC-1 epithelial tumor mucin is a glycoprotein which is abundantly expressed on a wide range of human adenocarcinomas, including those arising from breast, ovary and pancreas. MUC-1 mucin has been identified as a target for cytotoxic T cells in cancer patients. The aim of our work is to exploit the recognition of MUC-1 mucin by the immune system to develop an effective cancer vaccine. We hypothesize that the expression of MUC-1 mucin on dendritic cells, which are potent...

Want to see the full article?

• Purchase this article for only $3.00